Verrica Pharmaceuticals Inc. filed an application with the U.S. Food and Drug Administration seeking approval for its medicine VP-102 to treat a type of contagious skin disease.
The West Chester, Pa.-based medical dermatology company is studying VP-102 to treat molluscum contagiosum — an infection caused by a poxvirus that results in round, firm, painless bumps on the skin. The condition affects about six million people in the U.S., primarily children. There is no FDA-approved treatment for molluscum, the company said in a Sept. 16 press release.
The application was backed by positive data from two phase 3 trials, which showed that the drug helped achieve clearance of lesions on the skin.
VP-102 is also being evaluated by Verrica to treat verruca vulgaris, or common warts.
